TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06547203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab: 500 mg/m², intravenous infusion, once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab: 3 mg/kg, intravenous infusion, once every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan: 150 mg/m², intravenous infusion, once every 2 weeks.
Study: NCT05463458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition
Description: Standard of nutrition Care plus adjusted and calculated dose of omega-3 polyunsaturated fatty acids (PUFA) anti-oxidants.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: nutrition
Description: Standard of nutrition Care plus adjusted and calculated dose of omega-3 polyunsaturated fatty acids (PUFA) anti-oxidants.
Study: NCT05499156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placenal MSC derived exosomes
Description: placenta-MSCs derived exosomes Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of PlacentaMSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placenal MSC derived exosomes
Description: placenta-MSCs derived exosomes Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of PlacentaMSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial
Study: NCT05123027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Intervention to Link Overdose Survivors to Treatment (PILOT) Peer
Description: Participants will meet with the PILOT Peer consistently throughout the 6 months of study participation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment As Usual Peer
Description: Participants will receive recovery resources and standard of care procedures specific to the Emergency Department.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual Peer
Description: Participants will receive recovery resources and standard of care procedures specific to the Emergency Department.
Study: NCT04916886

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml
Description: Containing 0.5E10vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml
Description: Containing 0.5E10vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml
Description: Containing 0.5E10vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
Description: Containing 0.3E10vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
Description: Containing 0.3E10vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
Description: Containing 0.3E10vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
Description: Containing 0.3E10vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
Description: Containing 0.3E10vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
Description: Containing 0.3E10vp
Study: NCT05778708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai-Chi intervention
Description: The standardized 16-form Yang-style Tai-Chi exercise set will be adopted. Group classes will take place in a community center twice a week for 16 weeks, with each class lasting approximately 60 minutes. Classes will be taught by an experienced Tai-Chi master. Patients will be instructed to practice the Tai-Chi exercises at home at least 3 times a week (30 min each time for a total of 90 min). Patients will be provided with a daily exercise log to record their exercise type, frequency, and intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Description: The aerobic exercise class will be designed to cover both aerobic and resistance exercises. Group classes will take place in an exercise center twice a week for 16 weeks, with each class lasting approximately 60 minutes. Each class will be led by a certified exercise specialist. Patients will be provided with a daily exercise log to record their exercise type, frequency, and intensity.
Study: NCT00240864

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Study: NCT04844307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shorter duration higher frequency PT
Description: The standard PT session (30 mins) will be divided into two 15 minute sessions spread out during the day. Therefore, the total number of minutes of PT will not vary from the standard.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard PT
Description: The standard PT session is 30 minutes once daily. It routinely involves exercises designed to strengthen and increase mobility of the patient such as bed mobility, transfers, and ambulation. In this study group there will be no variation from this standard treatment.
Study: NCT06274125

Intervention type: PROCEDURE
Intervention: Robotic-Assisted Laparoscopic Radical Prostatectomy
Description: To evaluate kidney damage in patients undergoing robotic radical prostatectomy, NGAL measurement will be performed.
Study: NCT05770401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-Behavioral Cough Suppression Therapy
Description: Participants will access training modules to learn behavioral techniques and will implement them in daily life over a four-week period.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Participants will access training modules to learn behavioral techniques and will implement them in daily life over a four-week period.
Study: NCT05081076

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glazing
Description: The zirconia surface will be submitted to a vitrification procedure (glazing) in a specific ceramic oven using the Ceramill Stain \& Glaze Kit, following the manufacturer's instructions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polishing
Description: The zirconia surface will be submitted to a polishing procedure using a polishing rubbers kit in the sequence indicated by the manufacturer (EVE DIACERA Finishing and Polishing Kit, EVE Ernst Vetter GmbH - Germany).
Study: NCT05544994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Aerobic training will be performed 3 days a week for 12 weeks at 60%-%75 of their maximum hearth rate with 30 minutes total duration consisting of 5 min warm up and 5 min cool down period in treatment group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: Home exercise program will be given. This home program will include stretching, breathing, normal joint movement, for 3 to 5 days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise program
Description: Home exercise program will be given. This home program will include stretching, breathing, normal joint movement, for 3 to 5 days a week.
Study: NCT04972513

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Intervention: Nitric Oxide Breath Test
Description: Undergo nitric oxide breath testing

Intervention type: PROCEDURE
Intervention: Oscillometry
Description: Undergo airwave oscillometry

Intervention type: PROCEDURE
Intervention: Spirometry
Description: Undergo spirometry

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey

Intervention type: PROCEDURE
Intervention: Endothelial function
Description: Endothelial function will be assessed with the EndoPAT device, which measures changes in pressure from sensors placed on the fingertip
Study: NCT04894994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLX475
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV infusion
Study: NCT04412395

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin (Apolactoferrin)
Description: Apolactoferrin is an iron-free Lactoferrin (with very low iron saturation). Lactoferrin (Lf) is a natural glycoprotein that is found predominantly in milk. Lf represents a known component of the innate immune system present in neutrophil-specific granules and broadly distributed within the body fluids and exocrine secretions.
Study: NCT04229797

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular distalization using extra-radicular miniscrews
Description: Distalization of the Mandibular first molars using mandibular buccal shelf mini-screws in the presence of unerupted third molars

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular distalization using extra-radicular miniscrews
Description: Distalization of the Mandibular first molars using mandibular buccal shelf mini-screws in the presence of unerupted third molars
Study: NCT05386745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: A series of 10 weekly psychoeducational modules including information on psychosocial determinants of physical activity engagement, adherence and maintenance, as well as a number of other behaviour change tools, like reflection activities.
Study: NCT06036654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: infrared thermotherapy instrument
Description: Only a single target nail was chosen among multiple onychomycosis to receive local hyperthermia treatment.
Study: NCT05463783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy
Description: microRNA profiles of subjects on Biktarvy, will be compared with those who are on Symtuza, at various time points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symtuza
Description: microRNA profiles of subjects on Symtuza, will be compared with those who are on Biktarvy, at various time points.
Study: NCT04412395

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of excipient(s) will be administered
Description: Placebo of the equivalent excipient will be administered to placebo group
Study: NCT05927805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-bibliotherapy
Description: Participants in the intervention group will accept eight weekly sessions of e-bibliotherapy. The e-bibliotherapy will be delivered via the e-bibliotherapy app we develop and includes eight e-bibliotherapy sessions, each focusing on one active component that may affect a caregiver's mental well-being.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The control group will give access to the same e-bibliotherapy app, but only be authorized to access general daily living knowledge that is different from the intervention contents. They will also be asked to finish a session each week for eight weeks.
Study: NCT05956171

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular corticosteroid injection
Description: 5 ml blind intra-articular corticosteroid injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Hydrodilatation with corticosteroid injection
Description: 15 ml intra-articular injection to shoulder via anterior approach under ultrasound guidance
Study: NCT06396871

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: 75g of a standardized glucose solution followed by blood draw at 0, 30, 60, 90, 120 min

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: 75g of a standardized glucose solution followed by blood draw at 0, 30, 60, 90, 120 min

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: 75g of a standardized glucose solution followed by blood draw at 0, 30, 60, 90, 120 min

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: 75g of a standardized glucose solution followed by blood draw at 0, 30, 60, 90, 120 min

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: 75g of a standardized glucose solution followed by blood draw at 0, 30, 60, 90, 120 min

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: 75g of a standardized glucose solution followed by blood draw at 0, 30, 60, 90, 120 min

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: 75g of a standardized glucose solution followed by blood draw at 0, 30, 60, 90, 120 min

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver Ultrasound
Description: A crude assessment of liver status in order to identify the presence of steatosis or not will take place with ultrasound.
Study: NCT05401331

Intervention type: DEVICE
Group type: OTHER
Intervention: Treadmilll
Description: Hemodynamic changes before and after treadmill use

Intervention type: DEVICE
Group type: OTHER
Intervention: Treadmilll
Description: Hemodynamic changes before and after treadmill use

Intervention type: OTHER
Group type: OTHER
Intervention: mask
Description: mask
Study: NCT05789680

Intervention type: PROCEDURE
Intervention: Surgical treatment of parathyroid carcinoma
Description: Radical treatment of suspected parathyroid carcinoma should consist of parathyroidectomy and en bloc ipsilateral hemithyroidectomy and central lymph node dissection.
Study: NCT05934279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: All training exercise involve balance and strength improvement. Consist of 8 weeks of trainings per 2 trainings in each week, ongoing 45 minutes.
Study: NCT06396871

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver Ultrasound
Description: A crude assessment of liver status in order to identify the presence of steatosis or not will take place with ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver Ultrasound
Description: A crude assessment of liver status in order to identify the presence of steatosis or not will take place with ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver Ultrasound
Description: A crude assessment of liver status in order to identify the presence of steatosis or not will take place with ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver Ultrasound
Description: A crude assessment of liver status in order to identify the presence of steatosis or not will take place with ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver Ultrasound
Description: A crude assessment of liver status in order to identify the presence of steatosis or not will take place with ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver Ultrasound
Description: A crude assessment of liver status in order to identify the presence of steatosis or not will take place with ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan of the Liver
Description: FibroScan non-invasively measures the stiffness of the liver by capturing and calculating the speed of a shear wave as it travels through the liver (vibration controlled transient elastography).

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan of the Liver
Description: FibroScan non-invasively measures the stiffness of the liver by capturing and calculating the speed of a shear wave as it travels through the liver (vibration controlled transient elastography).

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan of the Liver
Description: FibroScan non-invasively measures the stiffness of the liver by capturing and calculating the speed of a shear wave as it travels through the liver (vibration controlled transient elastography).

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan of the Liver
Description: FibroScan non-invasively measures the stiffness of the liver by capturing and calculating the speed of a shear wave as it travels through the liver (vibration controlled transient elastography).

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan of the Liver
Description: FibroScan non-invasively measures the stiffness of the liver by capturing and calculating the speed of a shear wave as it travels through the liver (vibration controlled transient elastography).

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan of the Liver
Description: FibroScan non-invasively measures the stiffness of the liver by capturing and calculating the speed of a shear wave as it travels through the liver (vibration controlled transient elastography).

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan of the Liver
Description: FibroScan non-invasively measures the stiffness of the liver by capturing and calculating the speed of a shear wave as it travels through the liver (vibration controlled transient elastography).
Study: NCT05415982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: The intervention is a ketogenic diet based on high-fat ketogenic meals prepared by the study participants, complemented with ketogenic food products from Natural Ketosis and Vitaflo. Exogenous ketones are provided by Audacious Nutrition. The macronutrient composition of the ketogenic diet given approx.: Fat 87 E%, Carbohydrate 3 E%, Protein 10 E%,
Study: NCT06432205

Intervention type: PROCEDURE
Intervention: surgery
Description: any forms of surgery, such as all tumor resection, partial tumor resection and palliative tumor resection surgery
Study: NCT04908722

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Participants will receive intramuscular (IM) injections of Ad26.COV2.S.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Participants will receive intramuscular (IM) injections of Ad26.COV2.S.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Participants will receive intramuscular (IM) injections of Ad26.COV2.S.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Participants will receive intramuscular (IM) injections of Ad26.COV2.S.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Participants will receive intramuscular (IM) injections of Ad26.COV2.S.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Participants will receive intramuscular (IM) injections of Ad26.COV2.S.
Study: NCT05742854

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: C-sections operations
Description: Immediately after the delivery of the baby, uterotonic agents will be applied before the placenta is removed and by a manual check of the fundus of the uterus and the anterior wall, followed by an examination of the uterine tone by the surgeon

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: C-sections operations
Description: Immediately after the delivery of the baby, uterotonic agents will be applied before the placenta is removed and by a manual check of the fundus of the uterus and the anterior wall, followed by an examination of the uterine tone by the surgeon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin
Study: NCT05600179

Intervention type: DRUG
Intervention: Dexamethasone intravitreal implant
Description: Dexamethasone intravitreal implant
Study: NCT05983237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib Camrelizumab Temozolomide
Description: Fluzoparib 50-150mg bid po, d1-21, q3w Camrelizumab 200mg iv, d1, q3w Temozolomide 50mg/m2-200mg/m2 d1-5,q3w
Study: NCT05131490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A mobile application intervention developed for gynecological cancer patients receiving chemotherapy
Description: The mobile application will consist of modules. It is planned to include four education modules and consultancy modules in the application.~1. Module 1: It will consist of sub-categories with information to be prepared in line with the current literature on gynecological cancer types and treatments applied. There will be information and short videos that will strengthen coping with physical symptoms, especially from chemotherapy.~2. Module 2: In this area, there will be meditation and relaxation/breathing exercises, information on relaxing complementary therapies, anxiety reduction and stress management techniques videos and audio recordings.~3. Module 3: Current developments on gynecological cancers will be included.~4. Module 4: Encouraging recovery stories and videos of cancer survivors will be included.~5. Module 5: Counseling module. This is the area where patients who cannot find answers in the frequently asked questions section can ask questions to the research team.
Study: NCT04655482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Intravitreal injection of aflibercept using treat-and-extend regimen~:Three monthly loading injections followed by proactive treatment using TAE regimen. Extension of injection interval by 2 weeks. The maximum injection interval was set as 16 weeks.
Study: NCT05339828

Intervention type: PROCEDURE
Intervention: unroofing curettage
Description: Surgery was performed with the patient lying in the prone position under local anesthesia. The tract was identified by passing small artery forceps along its length and was then opened by cutting directly down onto the forceps. The sinus and all its tracts were completely unroofed, and the base was curetted to remove all necrotic content, hair, and granulation tissue using a dry gauze. The fibrotic back wall was left as intact as possible to avoid delayed healing. Hemostasis was achieved using diathermy with no drainage needed.